ANGPT2 and acute respiratory distress syndrome: Yet, while some early-phase clinical trials have not conclusively demonstrated a significant reduction in mortality among ARDS patients, multiple studies note diminished inflammatory biomarkers, enhanced markers of endothelial and epithelial repair (e.g., angiopoietin-2), and suggestive benefits in subgroups like younger patients or those receiving higher doses of viable cells.